Tertiary lymphoid structures signature predicts prognosis and clinical benefits from neoadjuvant chemotherapy and PD-1 blockade in colorectal adenocarcinoma
The CRC-specific TLS signature identifies patients with favorable prognosis and enhanced responses to chemotherapy and PD-1 blockade, including MSS CRC resistant to immune checkpoint blockade. TLS abundance reflects an immunogenic TME, offering a biomarker for personalized treatment strategies.
Authors
- Zhuoqing Xu (ORCID: https://orcid.org/0000-0002-3062-3183)
- Mengdi Chen (ORCID: https://orcid.org/0000-0003-4995-481X)
- Zichao Guo (ORCID: https://orcid.org/0000-0002-2288-1174)
- Ren Zhao (ORCID: https://orcid.org/0000-0003-0136-7851)
- Zhiliang Li (ORCID: https://orcid.org/0000-0002-5978-0457)
- Chao‐Yuan Huang (ORCID: https://orcid.org/0000-0002-9322-6062)
- Wenqing Jia (ORCID: https://orcid.org/0000-0001-9310-7728)
- Tianshuai Zhang (ORCID: https://orcid.org/0000-0002-4596-6832)
- Tao Zhang (ORCID: https://orcid.org/0000-0003-1048-4443)
- Wei Zhang (ORCID: https://orcid.org/0000-0001-5857-7230)
- Kun Liu (ORCID: https://orcid.org/0009-0008-5976-3009)
- Xi Cheng (ORCID: https://orcid.org/0000-0002-0009-8189)
- Fang Zheng (ORCID: https://orcid.org/0000-0002-2024-2424)
- Haoran Feng (ORCID: https://orcid.org/0009-0001-0874-0105)
Institutions
- Second Military Medical University (CN)
- Shanghai Jiao Tong University (CN)
- Ruijin Hospital (CN)
- Changhai Hospital (CN)
Publication Details
- Journal
- International Journal of Surgery
- Published
- 2025-05-29
- DOI
- https://doi.org/10.1097/js9.0000000000002568
- Citations
- 7
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 7.32